[Medworld News] October 18, 2018
Miracell (CEO Shin Hyun-soon), a stem cell company that promotes “the world’s safest stem cell technology,” has received approval from the Ministry of Food and Drug Safety to manufacture and sell medical devices.
CEO Shin Hyun-soon announced this in a recent letter to shareholders,
“Miracell’s technology competes with the world’s best, with five registered technology patents and nine patent applications. We are currently conducting a cell count to obtain an equivalence assessment to verify the excellence of our medical devices.”
Miracell holds five technology patents: a decanting kit for easy component separation and extraction, a centrifuge vessel for easy component separation and extraction, a swing rotor assembly for centrifuges, a centrifuge vessel, and a dual-wavelength laser device for skin treatment.
Miracell holds eight domestic patents and has one international PCT patent pending, including: a centrifuge vessel for easy component separation and extraction; a centrifuge kit for easy sample collection and component separation; a bucket for centrifuges; a component separation plotter for centrifuges; a vending machine for customized cosmetics manufacturing using AI; and a centrifuge equipped with a charging device.
Currently, Miracell’s stem cell therapy for diabetic lower extremity ischemia and knee arthritis has been designated as a limited new medical technology and has been selected for new support under the Health and Medical Technology Research and Development Project. Professor Chae Dong-sik (Orthopedic Surgery) at Catholic Kwandong University International St. Mary’s Hospital has demonstrated a cartilage regeneration rate of over 70% using autologous bone marrow stem cell transplantation using Miracell’s SmartPRep2 BMAC system, a new medical technology.
Professor Eun-soo Park (Department of Plastic Surgery) at Soonchunhyang University Bucheon Hospital is also giving hope to patients who had previously undergone limb amputation through autologous bone marrow stem cell therapy for diabetic lower extremity ischemia using Miracell’s Smart Prep 2 Bio-Mechanical System.
Reporter Myeong-in Park pmi0901@hanmail.net